Sunitinib Malate

苹果酸舒尼替尼

Report date: 2026/05/25 20:02:40
NMEFirst In Class

Base Information

Drug NameSunitinib Malate
Drug Alias Namesunitinibum纾癌特sunitinib舒癌特Aviga +[21] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 1 antagonistsVascular endothelial growth factor receptor 2 antagonists +[10] 
TargetsVascular endothelial growth factor receptor 1Stem cell growth factor receptorVascular endothelial growth factor receptor 3 +[9] 
Therapy Area/IndicationsUveal melanomaChronic eosinophilic leukemia (CEL)Diabetic macular oedema +[154] 
Global Approved IndicationsPancreatic neuroendocrine tumors (pNET)Carcinoma, Renal CellGastrointestinal Stromal Tumors
Approved Indications in ChinaPancreatic neuroendocrine tumors (pNET)Carcinoma, Renal CellGastrointestinal Stromal Tumors
Original Approved Country/TerritoryUnited States
Original Approved Date2006/01/26
Country/TerritoryCzechiaBelgiumBulgaria +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesScai TherapeuticsPfizer LtdPfizer Inc +[7] 
Inactive CompaniesUtah State UniversityDana-Farber Cancer InstituteArmy Medical University, China +[43] 
Active IndicationsPancreatic neuroendocrine tumors (pNET)Medullary thyroid cancer (MTC)Brain metastases +[20] 
Inactive IndicationsUveal melanomaChronic eosinophilic leukemia (CEL)Diabetic macular oedema +[134] 

Other Information

ATC CodeL01EX01
Related LinksWikipediaDrugBankKEGG